Some sunshine with a thunderstorm or two possible this afternoon. A few storms may be severe. High 83F. Winds WSW at 10 to 15 mph. Chance of rain 30%..
Tonight
Some clouds this evening will give way to mainly clear skies overnight. Low 62F. Winds NW at 5 to 10 mph.
Labcorp HoldingsLH shares soared 3.4% in the last trading session to close at $291.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.1% gain over the past four weeks.
Labcorp scored a strong price increase on investors’ optimism surrounding the company’s impending second quarter 2026 financial results, which is expected to release on July 30. Per the Zacks Consensus Estimate, the company’s quarterly revenues are expected to increase 5.4% year over year. Earnings per share is pegged at $4.79 for the second quarter, indicating 10.1% year over year improvement.
This medical laboratory operator is expected to post quarterly earnings of $4.79 per share in its upcoming report, which represents a year-over-year change of +10.1%. Revenues are expected to be $3.72 billion, up 5.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Labcorp, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on LH going forward to see if this recent jump can turn into more strength down the road.
Labcorp is part of the Zacks Medical Services industry. GoodRx Holdings, Inc.GDRX, another stock in the same industry, closed the last trading session 2% lower at $2.87. GDRX has returned 6.2% in the past month.
GoodRx's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.08. Compared to the company's year-ago EPS, this represents a change of -11.1%. GoodRx currently boasts a Zacks Rank of #3 (Hold).
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.Â
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.